PCSK9 and diabetes mellitus: Moreover, data extrapolated from Biobanks, e.g. the UK Biobank, refer to a healthy population with a low prevalence of glycaemic abnormality at baseline, whereas in clinical trials the effects of pharmacological PCSK9 inhibition on incident diabetes are estimated in patients that could already suffer from hyperglycaemia or diabetes.